

Estradiol and levonorgestrel transdermal patch

FemSeven Sequi®

(No. 20/02)

Merck Pharmaceuticals

Summary of Recommendation

6 December 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for general use within NHS in Scotland.

RECOMMENDATION

FemSeven Sequi offers an alternative sequential combined hormone replacement therapy (HRT) for the treatment of oestrogen deficiency symptoms in postmenopausal women. It is formulated as a transdermal patch and is the first sequential combined HRT patch to allow once weekly application. It is not licensed for the prophylaxis of osteoporosis.

Angela Timoney
Vice-Chairperson